We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Neutrophil-Lymphocyte Ratio Proves Possible Biomarker for ED

By LabMedica International staff writers
Posted on 30 May 2019
Erectile dysfunction is described as the impotency to obtain or sustain an erection sufficiently in order to enable convincing sexual intercourse. More...
Erectile dysfunction (ED) is estimated to affect about 75% of men over the age of 75 and 20% of men over the age of 20.

The association among many diseases, inflammatory markers and also their roles in the disease etiopathogenesis are important. The literature reveals that emerge and severity of ED are related with markers and mediators of inflammation and endothelial dysfunction.

Urologists at the Ordu University (Ordu, Turkey) and their colleagues evaluated 90 patients with erectile dysfunction (ED) and 94 healthy subjects from their internal medicine and urology clinics. As diagnosis criteria, they used the first five questions of International Index for Erectile Function. The duration of erectile dysfunction was asked and recorded. Height, weight and waist circumference of patients were measured.

The team performed total blood count, sedimentation, C-reactive protein, blood urea nitrogen (BUN), creatine, cholesterol, Low-density lipoprotein cholesterol (LDL-C) and High-density lipoprotein cholesterol (HDL-C) measurements of the patients were recorded. The neutrophil-lymphocyte ratio (NLR) was computed as the total neutrophil count separated by the total lymphocyte count.

The investigators found that there were statistically significant differences in terms of NLR between the control 1.038 (range: 0.507-1.92) and ED 2.38 (1.67.0-3.00) groups. According to the multivariate logistic regression analysis, duration of ED (Cut off: 7.5 month) predicted ED with 78.8% sensitivity and 63.1% specificity (AUC: < 0.001). Moreover, NLR (Cut off: 1.574) predicted ED with 81.8% sensitivity and 67.0% specificity (AUC: < 0.001) according to the multivariate logistic regression analysis.

The authors concluded that that the neutrophil-lymphocyte ratio was higher in patient group than the control group, and that the neutrophil-lymphocyte ratio (NLR) predicted ED and it might be helpful in diagnosing erectile dysfunction. The study was published on May 5, 2019, in the Urology Journal.

Related Links:
Ordu University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
All-in-One Molecular System
AIO M160
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.